Merck's V116 Vaccine Shows Promising Results in Phase 3 Studies at ISPPD: Key Findings and Real-World Impact
Merck's V116, a 21-valent pneumococcal vaccine, exhibits strong immunogenicity and coverage in diverse adult populations. Real-world data reveal its potential to combat pneumococcal diseases effectively.
Source: infectioncontroltoday.com